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Background: Many HIV-infected children in Southern Africa have
been started on antiretroviral therapy (ART), but loss to follow up
(LTFU) can be substantial. We analyzed mortality in children retained
in care and in all children starting ART, taking LTFU into account.
Patients and Methods: Children who started ART before the
age of 16 years in 10 ART programs in South Africa, Malawi,
Mozambique, and Zimbabwe were included. Risk factors for death in
the ﬁrst year of ART were identiﬁed in Weibull models. A meta-
analytic approach was used to estimate cumulative mortality at 1 year.
Results: Eight thousand two hundred twenty-ﬁve children (median
age 49 months, median CD4 cell percent 11.6%) were included; 391
(4.8%) died and 523 (7.0%) were LTFU in the ﬁrst year. Mortality at
1 year was 4.5% [95% conﬁdence interval (CI): 2.8% to 7.4%] in
children remaining in care, but 8.7% (5.4% to 12.1%) at the program
level, after taking mortality in children and LTFU into account.
Factors associated with mortality in children remaining in care
included age [adjusted hazard ratio (HR) 0.37; 95% CI: 0.25 to 0.54
comparing $120 months with ,18 months], CD4 cell percent (HR:
0.56; 95% CI: 0.39 to 0.78 comparing $20% with ,10%), and
clinical stage (HR: 0.12; 95% CI: 0.03 to 0.45 comparing World
Health Organization stage I with III/IV).
Conclusions: In children starting ART and remaining in care in
Southern Africa mortality at 1 year is ,5% but almost twice as high
at the program level, when taking LTFU into account. Age, CD4
percentage, and clinical stage are important predictors of mortality at
the individual level.
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INTRODUCTION
Antiretroviral therapy (ART) has become more widely
available in resource-limited settings in recent years.
1 Similar
virological response and relative reductions in mortality
compared with industrialized settings have been observed in
adult patients.
2,3 In sub-Saharan Africa, mortality is, however,
high in the ﬁrst months of ART because many patients start
therapy with advanced infection. Patients who start ARTwith
less advanced disease have mortality rates that are comparable
to the general population in the second year of ART.
3,4 Loss to
follow-up (LTFU) is a common unfavorable outcome in ART
programs in resource-limited settings.
5,6 LTFU introduces bias
in estimates of mortality at the level of the treatment program,
Received for publication December 9, 2009; accepted March 5, 2010.
From the *Institute of Social and Preventive Medicine, University of Bern,
Switzerland; †Lighthouse Trust, Lilongwe, Malawi; ‡Centre for Infectious
Disease Epidemiology and Research, School of Public Health and Family
Medicine, University of Cape Town, Cape Town, South Africa; §Perinatal
HIV Research Unit, Universityof the Witwatersrand, Johannesburg, South
Africa;
kUniversity of Witwatersrand Paediatric HIV Clinics (Harriet
Shezi Clinic, Chris Hani Baragwanath Hospital), Johannesburg, South
Africa; {Division of Infectious Diseases, Department of Medicine,
Universityof Stellenbosch and Tygerberg Academic Hospital, Cape Town,
South Africa; #University of Witwatersrand Paediatric HIV Clinics
(Rahima Moosa Mother and Child Hospital), Johannesburg, South Africa;
**Red Cross Children’s Hospital and the University of Cape Town, Cape
Town, South Africa; ††Paediatric Day Hospital, Maputo, Mozambique;
‡‡Newlands Clinic, Harare, Zimbabwe; §§McCord Hospital, Durban,
South Africa;
kkMe ´decins Sans Frontie `res, University of Cape Town, Cape
Town, South Africa; and {{The Desmond Tutu HIV Centre, Institute of
Infectious Disease and Molecular Medicine, University of Cape Town,
Cape Town, South Africa.
Supported by the National Institute of Allergy and Infectious Diseases and the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development (grant 1 U01 AI069924–01). The funder had no role in
study design, data collection and analysis, decision to publish, or
preparation of the article.
Presented in part [‘‘Mortality, loss to follow-up and transfer-out in pediatric
ART programs in Southern Africa’’ (abstract WEPEB276)] at the 5th IAS
Conference on HIV Pathogenesis, Treatment and Prevention; July 19–22,
2009; Cape Town, South Africa.
The IeDEA-SA participating sites are listed in Appendix I.
The authors declare that they have no conﬂict of interest.
Correspondence to: Dr. Lukas Fenner, MD, MSc, Institute of Social and
Preventive Medicine (ISPM), University of Bern, Finkenhubelweg 11,
CH-3012 Bern, Switzerland, (e-mail: lfenner@ispm.unibe.ch).
Supplemental digital content is available for this article. Direct URL citations
appear in the printed text and are provided in the HTML and PDF versions
of this article on the journal’s Web site (www.jaids.com).
Copyright  2010 by Lippincott Williams & Wilkins
524 | www.jaids.com J Acquir Immune Deﬁc Syndr   Volume 54, Number 5, August 15, 2010that is, mortality in all patients starting ART at a given site.
Efforts to improve program retention by tracing all or a sample
of patients LTFU have been introduced in some programs, and
mortality in patients LTFU was found to be substantially
higher than in patients retained in the program.
7
African children are disproportionately affected by the
HIV epidemic: an estimated 2.1 million children worldwide
lived with HIVat the end of 2007; 90% of them in sub-Saharan
Africa.
8 Mortality and program retention of children starting
ART are not well deﬁned at present, with substantial
heterogeneity between pediatric treatment programs.
9–15 We
examined early mortality and LTFU of HIV-infected children
starting ART in 10 sites participating in the International
epidemiologic Databases to Evaluate AIDS in Southern Africa
(IeDEA-SA). We estimated mortality and risk factors for death
in children retained in care, and mortality at the program level,
taking into account mortality among children LTFU.
PATIENTS AND METHODS
Study Population and Cohort Characteristics
The IeDEA-SA collaboration includes programs from
Botswana,Malawi,Mozambique,SouthAfrica,Zimbabwe,and
Zambia (www.iedea-sa.org). IeDEA-SA is part of IeDEA,
which includes similar networks in other regions of Africa,
Latin America and the Caribbean, Asia, and North America
(www.hiv-iedea.org).
16 Data are collected at each site as part of
routine monitoring atbaseline (ARTinitiation) and each follow-
up visit, using standardized deﬁnitions. Data from the different
sites are transferred to data centers at the Universities of Cape
Town, South Africa, or Bern, Switzerland, in a standardized
format and merged at regular intervals. Information on each
program is collected using standardized site assessments, which
are completed each year using the web-based World Health
Organization (WHO) Data Collector tool.
17 Descriptions on
program characteristics are based on the most recent site
assessment in 2008 and mainly reﬂect the situation toward the
end of the period of data collection for this study.
Eligibility Criteria and Outcomes
All treatment-naive children (age #16 years) who started
ART after 1998 were included in the analysis. Enrollment of pa-
tients and selection into care vary between sites (see Table, Sup-
plemental Digital Content 1, http://links.lww.com/QAI/A62).
Small sites with less than 100 eligible children were excluded.
Children were categorized into alive, dead, transferred out, and
LTFU. The primary outcome was death from all causes. A child
was considered LTFU if the last visit was more than 6 months
before the closure date for that site, with the closure date deﬁned
as the most recent visit date of each site recorded in the database.
Only children who commenced ARTat least 6 months before the
closure of the site databases could therefore be LTFU. Weight and
height measurements were converted to age-standardized and
sex-standardized z scores using WHO growth reference stand-
ards.
18,19 Clinical stage and immunological category were deﬁned
according to WHO guidelines.
20
Statistical Analysis
We used Weibull random effects regression models to
identify risk factors for death in children remaining in care.
The following variables were considered: age (,18 months,
18–59 months, 60–119 months, $120 months), gender, CD4
percentage (,10%, 10% to , 20%, $20%), WHO clinical
stage, and year of starting ART. Missing values for CD4
percentage and WHO clinical stage were imputed using
chained estimation with 10 imputation cycles.
21 The same
models were used to estimate cumulative mortality at 1 year
for each program. Program-speciﬁc mortality estimates were
then combined in random effects meta-analysis.
We calculated a weighted average of the mortality
observed in children remaining in care and mortality estimated
for children LTFU.
22 We obtained estimates of mortality in
children lost to programs from a meta-analysis of studies that
traced patients LTFU to ascertain their vital status.
7 This study
showed an inverse relation between mortality among those lost
to programs and the rate of LTFU (see Figure, Supplemental
Digital Content 2, http://links.lww.com/QAI/A63). We used
the mortality estimate that corresponded to the rate of LTFU
observed in a program to estimate overall program-level
mortality. For example, 0.8% of children were LTFU at year 1
in program C, whereas 12.3% were lost in program F.W e ,
therefore, assumed that 63.2% and 51.9%, respectively, of
children LTFU had died (see Table, Supplemental Digital
Content 3, http://links.lww.com/QAI/A64). Ninety-ﬁve per-
cent conﬁdence intervals (CIs) for estimates of program-level
mortality were obtained from Monte Carlo simulations.
We examined to what extent heterogeneity in program-
level mortality might be explained by differences in prognostic
factors at baseline. We adjusted analyses of children remaining
in care for age, gender, WHO clinical stage, CD4 percentage,
and starting year of ART and applied a cohort-speciﬁc
correction factor (adjusted mortality estimate divided by crude
estimate) to estimates and 95% CI of program-level mortality.
Adjusted estimates were centered and correspond to a hypo-
thetical population that is typical for the primary care settings
included in this study (age 59.7 months, 50.6% male, 53.4% in
WHO stage III, CD4 cell percentage 12.6%, and start of ART
in 2005). Considering the young median age of the cohort, we
used CD4 percentage in all age groups and thus avoided using
2 separate measures for immune deﬁciency (percentage and
count). All data were analyzed using Stata statistical software
version 10 (College Station, TX).
Ethical Approval
All study sites had local institutional review board or
ethics committee approval to collect data and participate in
IeDEA-SA.
RESULTS
Characteristics of Treatment Programs
Ten treatment programs in 4 countries (South Africa,
Malawi, Mozambique, and Zimbabwe) were included in the
present analysis. The ﬁgure in (Supplemental Digital
Content 4, http://links.lww.com/QAI/A65) shows the location
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http://links.lww.com/QAI/A62) shows the characteristics of
programs. Four sites are based in Cape Town (South Africa),
1 each in Soweto, Johannesburg, and Durban (South Africa),
1 in Lilongwe (Malawi), 1 in Maputo (Mozambique), and 1 in
Harare (Zimbabwe). Two of the 10 programs were tertiary care
sites, 8 were public programs, and 3 treated children only. All
programs were located in urban areas and started ART
according to clinical stage and CD4 percentage. At 4 sites,
ART in children younger than 12 months was initiated
according to revised WHO guidelines
23 toward the end of the
period of data collection.
Patient Characteristics
Table 1 summarizes patient characteristics at the start of
ART: a total of 8225 HIV-infected children were analyzed. The
3 largest programs (sites B, D, and G) contributed 4413
(53.7%) children; 3 sites with a total of 2153 (26.2%) patients
were from outside South Africa. Median age was 49 months
(range across sites 16–120 months), 2045 (24.9%) were
younger than 18 months (range 2.7% to 53.4%), 4159
(50.6%), were male (range 45.8% to 55.3%), and median
follow-up was 17.3 months (range 8.7 to 25.7 months).
Median CD4 percent at start of ART ranged from 8% to 15%
and the proportion of children with WHO clinical stage III/IV
from 63.7% to 96.9%. The most frequent initial ART regimen
was stavudine/lamivudine in combination with efavirenz
(37.4%), nevirapine (22.0%), or lopinavir/ritonavir (18.1%).
Children treated in tertiary care programs were younger
(median age 19 months versus 57 months, P , 0.0001) and
more likely to be in clinical stage III/IV (88.7% versus 75.3%,
P , 0.0001). Rates of transfer-out were higher for tertiary care
programs: 42.7% versus 7.7% in other sites, P , 0.0001.
Overall, 1176 (14.3%) had been transferred to another site
(range 0%–45.6%). A total of 7482 eligible children with at
least 6 months of follow-up could be included in calculations
of the rate of LTFU: 717 children (9.6%) were LTFU (range
across programs 1.9% to 14.2%).
TABLE 1. Baseline Characteristics and Outcomes of Children Starting ART in Each of 10 Treatment Programs in Southern Africa
Characteristic Site A Site B Site C* Site D Site E*
Patients, n (% of total children) 264 (3.2) 1086 (13.2) 266 (3.2) 2202 (26.8) 560 (6.8)
Age, median (IQR), mo 120 (81–159) 45 (16–86) 48 (19–84) 57 (22–92) 45 (21–80)
Age group, n (%), mo
,18 7 (2.7) 295 (27.2) 65 (24.4) 461 (20.9) 115 (20.5)
18–59 43 (16.3) 358 (32.9) 93 (35.0) 714 (32.4) 232 (41.4)
$60 214 (81.1) 433 (39.9) 108 (40.6) 1027 (46.7) 213 (38.1)
Sex
Male, n (%) 121 (45.8) 539 (49.6) 147 (55.3) 1116 (50.7) 290 (51.8)
Weight-for-age z score, n (%)
#23 29/70 (41.4) 86/367 (23.4) NA 162/612 (26.5) 8/42 (19.1)
CD4 cell percentage, median (IQR) NA 12 (6–17) NA 10 (6–15) 13 (9–19)
No. observations NA 585 NA 1577 290
Imputed values, median (IQR) 11 (6.4–16)‡ 13 (7.9–19) 14 (8.8–19)‡ 11 (6.7–16) 13 (9–19)
Viral load
Children with .1 million copies/mL, n (%) NA 55/487 (11.3) 2/112 (1.8) 316/1731 (18.3) 57/343 (16.6)
log10 copies/mL, median (IQR) NA 5.24 (4.70–5.70) 5.04 (4.65–5.56) 5.30 (4.72–5.87) 5.15 (4.42–5.68)
Hemoglobin (g/dL)
,8, n (%) 13/187 (7.0) 10/179 (5.6) 6/92 (6.5) 14/288 (4.9) 7/180 (3.9)
WHO immunological classiﬁcation
Advanced/severe, n (%) 128/152 (84.2) 490/586 (83.6) NA 1335/1587 (84.1) 266/324 (82.1)
WHO clinical stages
III and IV , n (%) NA NA 186/266 (69.9) 968/1520 (63.7) 422/560 (75.4)
Imputed values, n (%) 202 (76.3) 827 (76.2) 186 (69.9) 1481 (67.3) 422 (75.4)
TB treatment at start of ART, n (%) NA NA NA 534 (24.3) 91 (16.3)
Outcomes§
Months of follow-up, median (IQR) 14.9 (7.7–23.7) 18.0 (5.6–30.7) 25.7 (16.3–35.7) 16.6 (6.4–28.7) 24.3 (12.9–39.1)
Deaths, n (%) 24 (9.1) 49 (4.5) 3 (1.1) 113 (5.1) 11 (2.0)
LTFU, n (%)
k 6/231 (2.6) 125/965 (13.0) 5/258 (1.9) 176/1934 (9.1) 37/536 (6.9)
Transfer-out, n (%) 0 (0) 66 (6.1) 25 (9.4) 143 (6.5) 55 (9.8)
Alive and in care, n (%) 234 (88.6) 846 (77.9) 225 (84.6) 1753 (79.6) 455 (81.3)
Others/unknown, n (%) 0 (0) 0 (0) 8 (3.0) 17 (0.8) 2 (0.4)
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A total of 391 children (4.8%) died in the ﬁrst year of
ARTalthough in care. Figure 1 shows cumulative mortality at
1 year by treatment program. Mortality was substantially
higher in the ﬁrst 3 months of ART compared with later
months but did not signiﬁcantly change between 4–6 and 7–12
months after start of ART (Table 2). There was substantial
heterogeneity between programs as follows: mortality ranged
from 0.8% (95% CI: 0.2% to 3.1%) in site C to 16.8% (95%
CI: 14.2% to 19.9%) in site 1. The combined mortality
estimate for all programs from random effects meta-analysis
was 4.5% (95% CI: 2.8% to 7.4%) among children remaining
in care (Fig. 1). Mortality was higher in the tertiary care
programs compared with the other sites (13.5% versus 4.1%,
P = 0.014). Table 2 shows baseline variables associated with
the probability of death in children remaining in care from
crude and adjusted Weibull models. Younger age, lower CD4
cell, more advanced clinical stage, and starting ART in earlier
calendar years were associated with higher mortality.
Figure 2 shows program-level mortality at 1 year, after
taking mortality among children LTFU into account. Mortality
ranged from 1.3% (95% CI: 0.20% to 2.7%) in program C to
18.9% (95% CI: 15.9% to 22.1%) in program I. The combined
estimate was 8.7% (95% CI: 5.4% to 12.1%). Finally, Figure 3
shows program-levelmortality at 1 yearafter adjusting for age,
gender, CD4 percentage, WHO clinical stage, and year of
starting ART. Mortality ranged from 1.0% (95% CI: 0.2% to
2.1%) in program C to 10.2% (95% CI: 6.6% to 14.2%) in
program A. The higher mortality in tertiary care clinics was
clearly explained by differences in prognostic factors, but
some heterogeneity persisted due to lower mortality in
children treated in 2 community programs in South Africa.
TABLE 1. (continued) Baseline Characteristics and Outcomes of Children Starting ART in Each of 10 Treatment Programs in
Southern Africa
Characteristic Site F Site G Site H Site I† Site J† All sites
Patients, n (% of total children) 764 (9.3) 1125 (13.7) 405 (4.9) 854 (10.4) 699 (8.5) 8225 (100)
Age, median (IQR), mo 100 (58–143) 39 (19–76) 73 (33–109) 16 (6–51) 22 (9–60) 49 (18–92)
Age group, n (%), mo
,18 15 (2.0) 266 (23.6) 50 (12.3) 456 (53.4) 315 (45.1) 2045 (24.9)
18–59 188 (24.6) 478 (42.5) 112 (27.7) 216 (25.3) 215 (30.7) 2649 (32.2)
$60 561 (73.4) 381 (33.9) 243 (60) 182 (21.3) 169 (24.2) 3531 (42.9)
Sex
Male, n (%) 373 (48.8) 583 (51.8) 201 (49.6) 433 (50.7) 356 (50.9) 4159 (50.6)
Weight-for-age z score, n (%)
#23 23/104 (22.1) 185/1038 (17.8) 20/88 (22.7) 246/824 (29.9) 53/158 (33.5) 812/3302 (24.6)
CD4 cell percentage, median (IQR) 11 (7–16) 12 (8.5–17) 8 (4–13) 12 (7.6–19) 15 (9–23) 11.6 (7–17)
No. observations 245 627 185 823 379 4711
Imputed values, median (IQR) 12 (7.8–18) 13 (9–19) 11 (6–17) 12 (7.6–19) 15 (9.8–22) 12.6 (7.8–18.0)
Viral load
Children with .1 million copies/mL, n (%) NA NA 3/9 (33.3) 235/759 (31.0) 177/460 (38.5) 59/3901 (21.7)
log10 copies/mL, median (IQR) NA NA 5.88 (5.54–6.04) 5.66 (5.15–6.18) 5.78 (5.20–6.25) 5.40 (4.81–5.92)
Hemoglobin (g/dL)
,8, n (%) NA 68/416 (16.4) 24/243 (9.9) 129/820 (15.7) 62/468 (13.3) 334/2874 (11.6)
WHO immunological classiﬁcation
Advanced/severe, n (%) NA 499/627 (79.6) 191/211 (90.5) 693/823 (84.2) 311/398 (78.1) 4153/5035 (82.5)
WHO clinical stages
III and IV, n (%) 659/680 (96.9) 773/995 (77.7) NA 735/835 (88.0) 423/470 (90.0) 4487/5725 (78.4)
Imputed values, n (%) 726 (95.0) 875 (77.8) 314 (77.6) 752 (88.1) 613 (87.7) 6398 (77.8)
TB treatment at start of ART, n (%) NA 246 (21.9) NA NA NA NA
Outcomes§
Months of follow-up, median (IQR) 12.1 (3.3–28.8) 24.4 (13.5–35.7) 15.3 (5.4–26.1) 8.7 (4.0–18.1) 18.9 (6.1–33.5) 17.3 (6.7–30.0)
Deaths, n (%) 29 (3.8) 14 (1.2) 24 (5.9) 121 (14.2) 67 (9.6) 455 (5.5)
LTFU, n (%)
k 97/701 (13.8) 155/1090 (14.2) 13/346 (3.8) 69/777 (8.9) 34/644 (5.3) 717/7482 (9.6)
Transfer-out, n (%) 174 (22.8) 17 (1.5) 33 (8.2) 389 (45.6) 274 (39.2) 1176 (14.3)
Alive and in care, n (%) 418 (54.7) 935 (83.1) 322 (79.5) 273 (32.0) 313 (44.8) 5774 (70.2)
Others/unknown, n (%) 46 (6.0) 4 (0.4) 13 (3.2) 2 (0.2) 11 (1.6) 103 (1.3)
*Community-based program in South Africa.
†Tertiary level of care.
‡All values imputed.
§During the months of follow-up indicated.
kAmong children with .6 months of follow-up.
NA, not available.
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Figure 4 shows estimates of program-level mortality
assuming different mortality rates among children LTFU.
Taking LTFU up into account increased mortality estimates
compared with mortality in children retained in care, with
substantial changes being observed in programs with higher
rates of LTFU. The combined estimates from random effects
meta-analysis were less sensitive to mortality assumptions:
assuming that 25%, 50%, or 75% of children LTFU have died
resulted in combined estimates of mortality at 1 year of 7.2%
(95% CI: 4.2% to 10.2%), 8.4% (95% CI: 5.1% to 11.8%), and
9.7% (95% CI: 6.1% to 13.3%), respectively.
DISCUSSION
This collaborative analysis of 10 pediatric treatment
programs in 4 countries in Southern Africa found that 1-year
mortality in children starting ART varied across treatment
programs, with heterogeneity partly explained by differences
in prognostic factors at the start of ART, and differences in
LTFU. Our study illustrates that ignoring LTFU may lead to
substantial underestimation of mortality: mortality in children
remaining in care overall was below 5% but was estimated to
be about twice as high at the program level, when considering
deaths in children LTFU.
We examined mortality and risk factors for death in
children remaining in care and then estimated program-level
mortality. Previous analyses of mortality in patients starting
ART have generally truncated (censored) follow-up time in
patients LTFU, thus assuming that their mortality experience is
comparable to similar patients remaining in care.
12,15,24 This
assumption is problematic: many patients who are LTFU stop
taking ART and their mortality is high. In addition, patients
may not return for a follow-up appointment because they have
died. A meta-analysis of studies that traced adult patients
LTFU found that in sub-Saharan Africa mortality in patients
whose vital status could be ascertained was 46% (95% CI:
39% to 54%).
7 Interestingly, there was an inverse relation
between mortality among those LTFU and the rate of LTFU.
We took this into account and used the mortality estimate that
corresponded tothe rate of LTFU observed ina givenprogram.
A recent analysis of patients LTFU in the rural Me ´decins sans
Frontie `res program in Chiradzulu, Malawi, found that
mortality among patients LTFU was similar for adults and
children,
25 thus supporting our use of estimates from studies in
adults. Another study from Lilongwe, Malawi, described
a mortality estimate of 33% (CI: 20.4% to 48.4%) among
children LTFU (Weigel R, et al, unpublished data, 2010). The
high early mortality in infants and young children means that
adult estimates of mortality in those LTFU are not necessarily
applicable to cohorts which include a large proportion of very
young children.
26,27 Our sensitivity analyses showed, however,
that combined results were fairly robust to different mortality
assumptions for children LTFU.
The context of LTFU in children is different and more
complex compared with adults: children are dependent on
caregivers, and child outcomes may be related to those of their
parents. Even though caregivers are motivated to support
children to adhere to ART, the caregiver may change frequently
due to ill health, death, or adult migration. In addition, unlike
adult ART provision, most pediatric ART services remain
located in larger hospitals in urban centers, and the cost of
transport and inconvenience of having to attend separate clinics
for caregiver and child may contribute to LTFU.
28–30 In-
terestingly, at one of the few family centered ART clinics, it has
been shown that children whose caregiver is in HIV care at the
same clinic experience better outcomes.
31 The cost of pediatric
drugs and difﬁculty of giving children large amounts of
medicine which may be unpalatable are further obstacles to
effectively remaining in care.
28,30,32 Furthermore, many care-
givers are elderly grandparents for whom these obstacles may
become a substantial barrier to continuing on treatment.
27,30
FIGURE 1. Cumulative mortality at one year in children starting
ART and remaining in care in ten treatment programs in
Southern Africa. Circles show estimates from individual
programs, horizontal lines indicate 95% conﬁdence intervals,
and the diamond shows the combined estimate from random-
effects meta-analysis with 95% conﬁdence intervals.
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another clinic, perhaps a primary health care center closer to
their home, without notifying the program where ART was
started (‘‘silent’’ transfer-out).
Our study included children whowere treated in 10 ART
programs in 4 countries in Southern Africa, including pediatric
programs and programs mainly treating adults, and programs
at tertiary and lower levels of care. These sites may not
necessarily reﬂect the situation of this region as a whole: all
sites were located in urban areas and cohorts from South
Africa with a link to a research program predominated.
However, this is one of the largest pooled analyses of children
on ART ever done and from one of the regions of the world
most heavily affected by the HIV epidemic. Results should
therefore be applicable to many other children on ART.
Few previous studies reported mortality among children
starting ART: a pooled analysis from the Kids-ART-LINC
collaboration on over 2000 children on ART in sub-Saharan
Africa reported a probability of LTFU of 5.0% and a mortality
of 6.0% at 1 year,
9 which is slightly higher than the mortality
estimate in children remaining in care in the present study. The
number of children included was smaller than in the present
study and,more importantly,the analysis did not take mortality
among children LTFU into account. The estimate from the
Kids-ART-LINC analysis is therefore probably an underesti-
mate. A large program from Lusaka, Zambia, with 2398
children on ART showed a mortality rate of 6.6 deaths per 100
child-years, with an estimated cumulative mortality at 1 year
(from the Kaplan–Meier curve) of 7.9%. Children LTFU were
excluded from this analysis.
10 A pediatric ART treatment
program in Haiti indicated that 9% of children have died, and
10% were lost after a median follow-up time of 20 months.
33
The deﬁnition of LTFU was uniform across sites, but the
period of 6 months chosen for this deﬁnition may be too short
for some programs and too long for others. In the absence of
dedicated studies on the appropriate deﬁnition of LTFU, this
remains speculative. Follow-up of children who were trans-
ferred out was censored, thus assuming that their prognosis is
the same as that of comparable children remaining in care at
the site. Some children who were transferred out might,
however, have a better or worse prognosis than the children
remaining in a program. The proportion of children transferred
out was particularly high in tertiary care, and these children
will have been transferred to a lower level of care.
We observed differences between tertiary and other care
programs in baseline characteristics and a higher mortality in
tertiary care sites. The 2 tertiary programs are located in
a region in the Republic of South Africa with a large pediatric
ART network and a well functioning referral system; hence
patients who are younger and represent the severe end of the
pediatric HIV disease spectrum predominate at these sites.
Statistical adjustment for prognostic factors showed that if
children treated in tertiary centers were similar to the children
followed in the other programs, particularly with regard to age
TABLE 2. HRs for Death in the First Year of ART in Children Remaining in Care in 10 Treatment Programs in Southern Africa
Characteristic
Person-Years of
Follow-Up (yrs) No. Deaths
Unadjusted Adjusted
HR (95% CI) P* HR (95% CI) P*
Age (mo)
,18 1328 204 1 — ,0.0001 1 — ,0.0001
18–59 2100 72 0.29 (0.22–0.38) 0.29 (0.22–0.38)
60–119 2000 68 0.27 (0.20–0.36) 0.25 (0.19–0.34)
$ 120 759 47 0.42 0.29–0.61) 0.37 (0.25–0.54)
Sex
Male 3158 188 1 — 0.32 1 — 0.53
Female 3028 203 1.11 (0.91–1.35) 1.07 (0.87–1.30)
CD4 cell percentage
,10% 2248 196 1 — 0.0001 1 — ,0.0001
10% to ,20% 2809 121 0.52 (0.39–0.69) 0.48 (0.36–0.64)
$20% 1129 74 0.73 (0.52–1.02) 0.56 (0.39–0.78)
WHO clinical stages
III and IV 4637 356 1 — ,0.0001 1 — 0.0001
II 1118 32 0.41 (0.26–0.66) 0.46 (0.29–0.74)
I 431 3 0.10 (0.03–0.40) 0.12 (0.03–0.45)
Starting year of ART
before 2006 3671 254 1 — 0.49 1 — 0.0008
after 2006 2515 137 0.93 (0.75–1.15) 0.69 (0.55–0.86)
Time after starting ART
Month 1–3 92 273 1 — ,0.0001 1 — ,0.0001
Month 4–6 333 80 0.13 (0.10–0.18) 0.13 (0.10–0.18)
Month 7–12 5761 38 0.10 (0.08–0.13) 0.10 (0.08–0.13)
Models were adjusted for all variables listed in the table. Multiple imputation was used to deal with missing data for CD4 cell percent and clinical stage.
*The P Values are from Wald tests.
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observed in the other programs. Indeed, young age is an
important prognostic factor as shown in a recent collaborative
analysis of 33 European cohorts, which demonstrated that
mortality was almost double in children aged less than 2 years,
compared with older children.
26 Children treated at 2 township
programs in South Africa
3 had lower mortality, and this was
not explained by more favorable prognostic factors at baseline.
These programs mainly treat adult patients, and the children
followed there may represent a selected group of children with
a good prognosis. Other sources of heterogeneity might
include different patterns of transfer-out, different parental
outcomes related to children’s outcome, incorrect assumptions
on mortality in children LTFU, and incomplete or absent
adjustment for other prognostic variables, for example,
exposure to antiretroviral drugs for preventing mother-to-
child transmission. Furthermore, where programs do not have
the capacity to commence ART quickly, mortality on ART
may be lower due to survival bias among children who lived
long enough to access treatment. The (non-HIV–related)
background mortality in the different populations may also
have played a role.
4
Treatment programs should attempt to actively trace
patients considered as LTFU where this has not yet been done
and record outcomes in these patients LTFU. Where such
FIGURE 2. Cumulative mortality at one year at the level of the
program in ten treatment programs in Southern Africa. Circles
show estimates from individual programs, horizontal lines
indicate 95% conﬁdence intervals, and the diamond shows the
combined estimate from random-effects meta-analysis with
95% conﬁdence intervals.
FIGURE 3. Cumulative mortality at one year at the level of the
program in ten treatment programs in Southern Africa,
adjusted to correspond to a hypothetical primary care
population. Circles show estimates from individual programs,
horizontal lines indicate 95% conﬁdence intervals, and the
diamond shows the combined estimate from random-effects
meta-analysis with 95% conﬁdence intervals.
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included in this study, capacities should be increased to
intensifytheseactivities.Amodelingstudybasedonaprogram
in Co ˆte d’Ivoire found that interventions that enhance program
retention would both improve survival and be cost-effective by
international criteria.
34 An additional beneﬁt is that program-
level mortality can then be estimated by using double-
sampling designs to account for mortality among children
LTFU.
35,36 For example, data from an outreach program have
been used to adjust mortality estimates from an adult treatment
program in Kenya.
37,38 An important assumption made by this
method is that a random sample of patients LTFU was selected
and that the vital status of everyone from that sample was
ascertained. These assumptions are not generally met: patients
to be traced tend to be selected according to their assumed
place of residence, excluding patients who live far from the
treatment site, and typically about a third of patients cannot be
located.
7 Our approach is useful for sensitivity analysis in
programs where no dedicated tracing studies are available and
to test the robustness of estimates based on the results of
tracing activities.
In conclusion, our study indicates that mortality of HIV-
infectedchildrenstartingARTinSouthernAfricaissubstantially
higher than the mortality directly observed in treatment
programs. A better understanding of outcomes in children
LTFU and children transferred out of programs is required, and
the determinants of LTFU and transfer-out need to be deﬁned.
Dedicated ﬁeld studies tracing children LTFU and studies
linking data from treatment programs with routine mortality data
from national death registries are of high priority. It is important
both from a clinical and programmatic point of view to ensure
capacitytotracethisvulnerablepatientgroupassoonaspossible
after a missed clinic visit.
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